Darolutamide 600 mg twice daily

DRUG2 trials

Sponsors

Bayer, West China Hospital

Conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Prostate Cancer

Phase 2

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

CompletedNCT05171387

BayerProstate Cancer

Start: 2021-11-30End: 2025-02-24Updated: 2026-06-30

PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC

Not yet recruitingNCT07649421

West China HospitalMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Start: 2026-09-15End: 2031-10-01Target: 254Updated: 2026-09-10